Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,118.47
(
-0.04%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: lumpy9200 post# 52914

Monday, 10/01/2007 2:47:28 PM

Monday, October 01, 2007 2:47:28 PM

Post# of 257580
AMLN – A tidbit from NVO’s UBS webcast that may interest you: the presenter said that inhaled insulin is all but doomed to be a non-factor in the market due to the advent of GLP-1 drugs. The premise is that GLP-1 drugs will routinely be added to a regimen that includes long-acting, basal insulin.

What makes this admission remarkable is that NVO is one of the companies who has an inhaled-insulin program!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today